ENZN Enzon Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. OTC: ENZN

Price (delayed)

$0.339

Market cap

$25.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.04

Enterprise value

-$23.03M

Highlights
ENZN's revenue has surged by 66% since the previous quarter
The gross profit has soared by 66% from the previous quarter
The equity has grown by 14% YoY but it has contracted by 8% from the previous quarter
The company's EPS fell by 33% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://enzon.com/
Peers: NKTR ENTA AMGN XOMA

Key stats

What are the main financial stats of ENZN
Market
Shares outstanding
74.21M
Market cap
$25.16M
Enterprise value
-$23.03M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.97
Price to sales (P/S)
35.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-32.26
Earnings
Revenue
$714,000
EBIT
-$834,000
EBITDA
-$834,000
Free cash flow
-$794,000
Per share
EPS
-$0.04
Free cash flow per share
-$0.01
Book value per share
$0.09
Revenue per share
$0.01
TBVPS
$0.65
Balance sheet
Total assets
$48.25M
Total liabilities
$41.91M
Debt
$0
Equity
$6.34M
Working capital
$47.81M
Liquidity
Debt to equity
0
Current ratio
111.17
Quick ratio
111.04
Net debt/EBITDA
57.78
Margins
EBITDA margin
-116.8%
Gross margin
100%
Net margin
-117.8%
Operating margin
-117.5%
Efficiency
Return on assets
-6.1%
Return on equity
-36%
Return on invested capital
N/A
Return on capital employed
-1.7%
Return on sales
-116.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENZN stock price

How has the Enzon Pharmaceuticals stock price performed over time
Intraday
-3.14%
1 week
-5.81%
1 month
-6.33%
1 year
111.88%
YTD
36.47%
QTD
-10.17%

Financial performance

How have Enzon Pharmaceuticals's revenue and profit performed over time
Revenue
$714,000
Gross profit
$714,000
Operating income
-$839,000
Net income
-$841,000
Gross margin
100%
Net margin
-117.8%
ENZN's net margin has surged by 93% year-on-year and by 52% since the previous quarter
ENZN's operating margin has soared by 93% YoY and by 52% from the previous quarter
ENZN's revenue has surged by 66% since the previous quarter
The gross profit has soared by 66% from the previous quarter

Growth

What is Enzon Pharmaceuticals's growth rate over time

Valuation

What is Enzon Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.97
P/S
35.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-32.26
The company's EPS fell by 33% YoY
The stock's price to book (P/B) is 99% more than its 5-year quarterly average of 2.0 but 19% less than its last 4 quarters average of 4.9
The equity has grown by 14% YoY but it has contracted by 8% from the previous quarter
The P/S is 75% below the last 4 quarters average of 143.1 and 24% below the 5-year quarterly average of 46.3
ENZN's revenue has surged by 66% since the previous quarter

Efficiency

How efficient is Enzon Pharmaceuticals business performance
Enzon Pharmaceuticals's return on equity has shrunk by 101% YoY and by 11% QoQ
The company's return on sales has surged by 93% YoY and by 52% QoQ
ENZN's return on assets has surged by 56% year-on-year and by 19% since the previous quarter

Dividends

What is ENZN's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Enzon Pharmaceuticals financials performed over time
Enzon Pharmaceuticals's total assets is 15% more than its total liabilities
ENZN's quick ratio is up by 6% since the previous quarter
The current ratio has increased by 6% from the previous quarter
ENZN's debt is 100% smaller than its equity
The equity has grown by 14% YoY but it has contracted by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.